Group 1 - The company announced the convening of the third meeting of the fourth board of directors and the third meeting of the fourth supervisory board on August 20, 2025 [2] - The company approved a proposal to use temporarily idle raised funds for cash management, with a limit not exceeding RMB 155 million [2] - The cash management will involve purchasing safe and liquid principal-protected financial products, ensuring that it does not affect the construction of investment projects and normal operations [2]

Core Points - The company announced a plan to use idle self-owned funds for cash management, with a maximum amount of RMB 105,000.00 million [1] - The cash management products to be purchased will be high-security, good liquidity, and capital-preserving [1] - The authorization period for this plan is 12 months from the date of the board's approval, allowing for rolling use of funds within the specified limit [1]

Group 1 - The core point of the article is that Saikohide announced the approval of several proposals during the third meeting of its fourth supervisory board [2] Group 2 - The announcement was made on the evening of August 21 [2] - The proposals included the agenda and summary of the meeting [2]

Core Viewpoint - The company, Saikexide, announced the approval of multiple proposals during the third meeting of its fourth board of directors on the evening of August 21 [2] Group 1 - The board meeting reviewed and approved the proposal regarding the summary and other related matters [2]

Core Viewpoint - The company reported a decline in both revenue and net profit for the first half of 2025 compared to the previous year [1] Financial Performance - The company achieved operating revenue of 139 million yuan, representing a year-on-year decrease of 12.62% [1] - The net profit attributable to shareholders was 47.9999 million yuan, down 23.47% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 46.2395 million yuan, reflecting a year-on-year decline of 25.74% [1] - Basic earnings per share were reported at 0.46 yuan [1]

Core Viewpoint - The company reported a decline in both revenue and net profit for the first half of 2025, primarily due to the impact of medical insurance cost control policies on the demand in the in vitro diagnostic industry [1] Financial Performance - The company achieved an operating revenue of 139 million yuan, representing a year-on-year decrease of 12.62% [1] - The net profit attributable to the parent company was 47.9999 million yuan, down 23.47% year-on-year [1] - The basic earnings per share stood at 0.46 yuan [1] Industry Impact - The decline in revenue is attributed to the effects of medical insurance cost control policies on the demand within the in vitro diagnostic sector [1]

Meeting Overview - The third meeting of the fourth Supervisory Board of Beijing Saike Xide Technology Co., Ltd. was held on August 20, 2025, with all three supervisors present [1] - The meeting was chaired by Mr. Zhang Ying, and the notice was sent to all supervisors via email on August 8, 2025 [1] Financial Report Approval - The Supervisory Board approved the 2025 semi-annual report and its summary, confirming that the preparation and review processes complied with relevant laws and internal regulations [1] - The report accurately reflects the company's financial status and operational results for the first half of 2025, with no violations of confidentiality found during the preparation process [1] Fund Management Reports - The Supervisory Board approved the special report on the storage and actual use of raised funds, confirming compliance with legal regulations and that the use of funds aligns with previously disclosed information [2] - The company plans to use up to RMB 155 million of idle raised funds for cash management, purchasing safe and liquid principal-protected cash management products, with a 12-month authorization period [2] - The Supervisory Board also approved the use of up to RMB 1.05 billion of idle self-owned funds for cash management under similar conditions, ensuring no impact on the company's main business operations [3]

Core Viewpoint - The company plans to utilize temporarily idle raised funds for cash management to enhance fund efficiency while ensuring that it does not affect the normal operation of investment projects and the safety of the raised funds [2][3][6]. Summary by Sections 1. Basic Situation of Raised Funds - The company issued 20,412,000 shares at a price of 50.35 RMB per share, raising a total of 1,027.74 million RMB, with a net amount of 924.27 million RMB after deducting issuance costs [1]. 2. Previous Use of Idle Funds - The company approved the use of up to 300 million RMB of temporarily idle raised funds for cash management, ensuring it does not impact project construction or normal operations [2]. 3. Current Cash Management Plan - The company intends to use up to 155 million RMB of temporarily idle raised funds for cash management, with a rolling usage period of 12 months from the board's approval [3]. 4. Implementation and Disclosure - The board authorizes management to make cash management decisions and sign relevant legal documents, with the finance department responsible for implementation [4]. 5. Impact on Daily Operations - The use of idle funds for cash management is expected to improve fund efficiency and increase returns for the company and shareholders without significantly impacting future business operations or financial status [4]. 6. Review and Opinions - The supervisory board agrees that using idle funds for cash management enhances fund efficiency and does not change the purpose of the raised funds or harm shareholder interests [5][6]. 7. Sponsor's Verification Opinion - The sponsor confirms that the company's plan to use idle funds for cash management complies with relevant regulations and does not affect the normal progress of investment projects [7].

Core Viewpoint - The report highlights the financial performance and operational challenges faced by Beijing Succeeder Technology Inc. in the first half of 2025, particularly due to the impact of medical insurance cost control policies on the in vitro diagnostic industry. Financial Performance - The company's revenue for the first half of 2025 was approximately 138.96 million RMB, a decrease of 12.62% compared to the same period last year [4] - Total profit amounted to about 55.22 million RMB, reflecting a decline of 23.63% year-on-year [4] - The net profit attributable to shareholders was approximately 48.00 million RMB, down 23.47% from the previous year [4] - The net cash flow from operating activities was about 37.24 million RMB, a decrease of 28.55% compared to the same period last year [4] - The basic earnings per share were 0.46 RMB, down 22.03% year-on-year [4] Industry Overview - The company operates in the in vitro diagnostic sector, specifically focusing on thrombus and hemostasis diagnostics, which is part of the broader medical device manufacturing industry [5][6] - The in vitro diagnostic market in China exceeded 100 billion RMB in 2021, with a compound annual growth rate of 24.8% from 2015 to 2019 in the coagulation diagnostics segment [6][7] - The demand for coagulation testing is expected to recover in 2023 as hospital diagnostic activities resume, although growth may slow due to medical insurance cost control and compliance issues [6][8] Technological and Product Development - The company has developed a core technology cluster covering instruments, reagents, and consumables, with 15 core technologies and 46 patents, including 15 invention patents [12][16] - The company’s products include automated testing instruments and reagents for coagulation, blood rheology, and platelet aggregation, which are essential for the prevention, screening, diagnosis, and monitoring of thrombotic and hemorrhagic diseases [14][15] - The company is actively involved in setting industry standards and has contributed to the development of various national standards for diagnostic products [13][16] Market Dynamics - The in vitro diagnostic industry is characterized by high technical requirements and significant market potential, driven by advancements in medical technology and increasing health awareness among the population [7][8] - The implementation of centralized procurement policies by the National Medical Insurance Administration has pressured prices and profit margins in the in vitro diagnostic sector, favoring domestic leading enterprises [10][11] - The company is positioned to benefit from the ongoing reforms in medical insurance payment systems, which aim to enhance efficiency and control costs in healthcare delivery [9][10]

北京赛科希德科技股份有限公司2025 年半年度报告摘要 公司代码：688338 公司简称：赛科希德 北京赛科希德科技股份有限公司 北京赛科希德科技股份有限公司2025 年半年度报告摘要 第一节 重要提示 规划，投资者应当到上海证券交易所网站 http://www.sse.com.cn/网站仔细阅读半年度报告全文。 公司已在本报告中详细阐述在经营过程中可能面临的各种风险，请查阅本报告"第三节管理层讨 论与分析"之"四、风险因素"，敬请投资者注意投资风险。 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 不适用 □适用 √不适用 第二节 公司基本情况 公司股票简况 公司股票简况 | 股票种类 | 股票上市交易所 股票简称 | | 股票代码 | 变更前股票简称 | | | --- | --- | --- | --- | --- | --- | | 人民币普通股（A股） | 上海证券交易所科创板 | | 688338 赛科希德 | 不适用 | | | 公司存托凭证简况 | | | | | | | □适用 √不适用 | | | | | | | 联系人和联系方式 | | | | | | | 联 ...